Abstract

This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.


Claims
CPC Classifications
Download PDF
Document Preview
Document History
  • Publication: May 23, 2017
  • Application: Dec 28, 2015
    US US 201514998352 A
  • Priority: Dec 28, 2015
    US US 201514998352 A
  • Priority: Nov 27, 2013
    US US 201314092323 A
  • Priority: Apr 23, 2012
    US US 201213453789 A
  • Priority: May 12, 2008
    US US 11886108 A
  • Priority: Mar 29, 2005
    US US 9608205 A
  • Priority: Mar 29, 2004
    US US 55759904 P

Download Citation


Sign in to the Lens

Feedback